News and Events

Follow our latest news and events that we are participating in.

More about us

Meet Immuneed at NLS days 2018 in Stockholm!

Meet us at Nordic Life Science Days in Stockholm Waterfront, September 10-12. During the conference Justyna Leja-Jarblad, COO will be available for partnering meetings. If you are interested in our Immuno-Service, potential collaboration or insights regarding preclinical drug development, contact us through partneringONE.

Read more

Immuneed is one of the winners of the local business award Bona Postulata 2018

We are proud to announce that Immuneed is one of the winners of the Bona Postulata prize 2018, alongside our collaborators, Clinical Trial Consultants (CTC).

Read more

Meet Immuneed at Bio-Europe Spring 2018 in Amsterdam!

Join us at BIO-Europe Spring in Amsterdam March 12-14!  We are open to partnering meetings throughout the conference. Come and talk to us about our Immuno-Service, Immuno-Oncology, potential collaboration, or anything that interests you!

Read more

Immuneed to pitch at Life Science Dagen

By invitation from Dagens Medicin Agenda Justyna Leja-Jarblad, Service Manager and Business Development at Immuneed held a pitch at Life Science Dagen on December 5.

Read more

Immuneed shows unique immunomodulating drug-safety evaluation assay and new strategy for therapeutic cancer vaccination

Immuneed, a Swedish life science biotech company, today announced the publication of two key scientific publications, supporting both its immuno-service and its immuno-oncology offerings. The articles demonstrate Immuneed’s unique whole blood loop assay, a tool to predict first-infusion reactions of immunotherapeutics, and a novel targeting and adjuvant strategy to improve T cell responses that can be used for cancer vaccines.

Read more

Immuneed secures SEK 9M

Immuneed has secured SEK 9M in an oversubscribed financing round. The funding will support the pre-clinical work of our Immuno-Oncology cancer vaccine and be used to increase marketing of the companys analysis service. The new funding secures financing of our pre-clinical program for the cancer vaccine and further engagement for contract manufacturing.

Read more

Quick Links

Dag Hammarskjölds väg 10B | 752 37 Uppsala, Sweden |